Gigantomastia and Macroprolactinemia Responding to Cabergoline Treatment: A Case Report and Minireview of the Literature

Table 1

Biochemical and hormonal profile of the patient.

	Basal	1st month	2nd month	3rd month	5th month
Glucose (mg/dL)	74		79	72	71
Creatinine (mg/dL)	0.74		0.74	0.78
ALT (U/L)	16	11	11	11	16
TSH (IU/mL)	1.57	1.53	2.83	3.03	2.85
Free T4 (ng/dL)				1.04	1
Prolactin before PEG precipitation (ng/mL)	91.38	2.08	2.58	1.64	1.6
Prolactin after PEG precipitation (ng/mL)	10.22	0.78	0.82	0.69	0.65
Macroprolactin (%)	22.37	70	63.57	84.15	81.25
FSH (mIU/mL)	4.04			22.74
LH (mIU/mL)	4.54			12.69
Estradiol (pg/mL)	117.8			99.83
Progesterone (ng/mL)				0.55
GH (ng/mL)	0.03
IGF-1 (ng/mL)	115.3
Cortisol (g/dL)	16.07
ACTH (pg/mL)	13.64
-HCG (mIU/mL)	0.1			0.1

Glucose (74–106 mg/dL), creatinine (0.5–1.2 mg/dL), ALT (0–33 U/L), TSH (0.27–4.2 IU/mL), free T4 (0.9–1.7 ng/dL), prolactin (6–29.9 ng/mL), macroprolactin (0–40% positive, 40–60% borderline, and >60% negative), FSH (1.7–21.5 mIU/mL), LH (1–96 mIU/mL), estradiol (12.5–498 pg/mL), progesterone (0.1–3 ng/mL), GH (0–5 ng/mL), IGF-1 (94–252 ng/mL), cortisol (6.2–19.4 g/dL), ACTH (0–60 pg/mL), and -HCG (0–5 mIU/mL).